Taysha Gene Therapies (TSHA) Research & Development (2020 - 2026)
Taysha Gene Therapies' Research & Development was $38.64 million in Q2 2026, up 91.8% from $20.14 million a year earlier and up 14.3% from the prior quarter.
Powered by 
Analysis
Taysha Gene Therapies (TSHA) Research & Development (2020 - 2026) Analysis & Trends
On a trailing twelve-month basis, Taysha Gene Therapies' Research & Development was $123.14 million through Jun 30, 2026, up 86.6% year-over-year; for FY2025, it came in at $86.4 million, up 30.9% from FY2024.
- Research & Development shows a five-year compound annual growth rate of 22.1% (FY2020 to FY2025).
- In earlier years, Research & Development was $66 million in FY2024 (+16.2%), $56.78 million in FY2023 (-37.7%), $91.17 million in FY2022 (-30.9%) and $131.94 million in FY2021 (+313.7%).
- The Q2 2026 figure marks the highest quarterly Research & Development since Q3 2021.
- Compared with a year earlier, Research & Development has increased for five straight quarters, with growth averaging 50.1% over the last eight quarters.
- The best year-over-year quarter for Research & Development over five years was Q3 2021 (growth of 257.5%); the worst was Q1 2023 (a decline of 67.2%).
- Per Business Quant data, TSHA's Research & Development in the three quarters before Q2 2026 was $33.81 million (Q1 2026), $24.95 million (Q4 2025) and $25.75 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Taysha Gene Therapies | 1.52 Bn | 173.19 Mn | - | 38.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 38.64 Mn |
| Mar 31, 2026 | 33.81 Mn |
| Dec 31, 2025 | 24.95 Mn |
| Sep 30, 2025 | 25.75 Mn |
| Jun 30, 2025 | 20.14 Mn |
| Mar 31, 2025 | 15.57 Mn |
| Dec 31, 2024 | 15.33 Mn |
| Sep 30, 2024 | 14.95 Mn |
| Jun 30, 2024 | 15.07 Mn |
| Mar 31, 2024 | 20.66 Mn |
| Dec 31, 2023 | 12.68 Mn |
| Sep 30, 2023 | 11.79 Mn |
| Jun 30, 2023 | 19.79 Mn |
| Mar 31, 2023 | 12.51 Mn |
| Dec 31, 2022 | 12.71 Mn |
| Sep 30, 2022 | 16.77 Mn |
| Jun 30, 2022 | 23.51 Mn |
| Mar 31, 2022 | 38.18 Mn |
| Dec 31, 2021 | 37.92 Mn |
| Sep 30, 2021 | 39.53 Mn |
API Access
Taysha Gene Therapies Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=TSHA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "TSHA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=TSHA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();